Postmenopausal Women
at High Risk for Breast Cancer Needed for New Prevention Study
Behind the Cancer Headlines®
Healthy, post-menopausal women at high risk for breast cancer
may be eligible to participate in a major new international study to determine
whether the drug
exemestane
can prevent the disease. UC Davis Medical Center is the first center in the
"Exemestane
may present a new breakthrough in the prevention of breast cancer, and has the
potential to greatly decrease the risk of this deadly disease, with fewer side
effects than currently available preventive medications," said John Robbins,
professor of general medicine at UC Davis School of Medicine and
Exemestane is one of a new class of anti-cancer medications known as aromatase inhibitors. Aromatase inhibitors have shown promise in preventing breast cancer recurrences in women previously treated for the disease, but have not yet been clinically studied as a way to prevent breast cancer in high-risk women. The new study is the first designed to answer this question. In addition, the new study will determine whether exemestane plus an anti-inflammatory drug is more effective at preventing breast cancer than exemestane alone.
The drug tamoxifen has already been shown to prevent breast cancer in high-risk women, but many women have found its side effects, including hot flashes, unacceptable. Preliminary research suggests that exemestane will have fewer side effects than tamoxifen.
For the purposes of the study, women are considered at high risk of developing breast cancer if they have had a prior breast biopsy that yielded atypical findings, have had a previous ductal carcinoma (localized breast cancer), have a strong family history of breast cancer or are age 60 or older, among other factors. All participants must be between the ages of 40 and 75, with no history of invasive breast cancer, and in general good health.
Study volunteers will be randomized into one of three groups.
In the first group, participants will receive oral
exemestane
daily for five years along with an oral placebo for the first three years. In
the second group, participants will receive oral
exemestane
daily for five years along with oral
celecoxib, an anti-inflammatory agent, for the
first three years. In the third group, patients will receive an oral placebo
daily for five years. The study will be "double-blind," meaning that neither
the participants nor the study investigators will know who is taking the
placebo until after the study is over.
For more information about the exemestane study at UC Davis Medical Center, please contact Elizabeth Winward at 916-734-5562 or e-mail Robbins directly at jarobbins@ucdavis.edu.
SOURCE: